<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916821</url>
  </required_header>
  <id_info>
    <org_study_id>00001</org_study_id>
    <nct_id>NCT04916821</nct_id>
  </id_info>
  <brief_title>Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19)</brief_title>
  <official_title>Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trabzon Kanuni Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trabzon Kanuni Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose: To investigate the effect of propolis, a food supplement product, on healing&#xD;
      parameters in patients with COVID 19. Secondary purpose: To provide a new supportive&#xD;
      treatment in Covid 19 treatment. In the present study to examine the effect of the use of&#xD;
      propolis on healing parameters (laboratory and imaging) in patients with COVID 19; Propolis,&#xD;
      which has antiviral properties, has also been used in humans in the COVID19 pandemic as of&#xD;
      2020. However, in these studies, an alcohol-soluble extract of propolis was used. Despite the&#xD;
      disadvantages of its use in alcohol, it is clear that water and olive oil extracts of&#xD;
      Propolis are safer for humans. Therefore, water extracts of propolis will be used in the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>first group treated with water extracts of propolis second group treated with olive oil extracts of propolis including perga third group treated with no bee product</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radiological</measure>
    <time_frame>Change from Baseline Lung Tomography Findings(Peripheral ground-glass opacities) at one week</time_frame>
    <description>Lung tomography findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory parameters-2: ESR</measure>
    <time_frame>Change from Baseline ESR findings at one week</time_frame>
    <description>ESR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory parameters-3: CRP</measure>
    <time_frame>Change from Baseline CRP findings at one week</time_frame>
    <description>CRP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory parameters-4: D-Dimer</measure>
    <time_frame>Change from Baseline D-Dimer findings at one week</time_frame>
    <description>D-Dimer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory parameters-5: Troponin</measure>
    <time_frame>Change from Baseline Troponin findings at one week</time_frame>
    <description>Troponin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory parameters-6: sO2</measure>
    <time_frame>Change from Baseline sO2 findings at one week</time_frame>
    <description>sO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory parameters-1: CBC</measure>
    <time_frame>Change from Baseline CBC findings at one week</time_frame>
    <description>CBC</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>water extract of propolis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olive oil extract of propolis including perga</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group (patients not given any investigational product)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>propolis</intervention_name>
    <description>Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules</description>
    <arm_group_label>olive oil extract of propolis including perga</arm_group_label>
    <arm_group_label>water extract of propolis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 18 who do not need a ventilator who are inpatient in the&#xD;
             Covid service&#xD;
&#xD;
          -  Patients under the age of 60 who do not need a ventilator who are inpatient in the&#xD;
             Covid service&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients do not have oral intake&#xD;
&#xD;
          -  patients whose informed consent form is not approved&#xD;
&#xD;
          -  patients who need a ventilator&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  children&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betül Değer Kulaksız, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Trabzon Kanuni Education and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trabzon Faculty of Medicine , Health Science University</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Berretta AA, Silveira MAD, Cóndor Capcha JM, De Jong D. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. Biomed Pharmacother. 2020 Nov;131:110622. doi: 10.1016/j.biopha.2020.110622. Epub 2020 Aug 17. Review.</citation>
    <PMID>32890967</PMID>
  </reference>
  <reference>
    <citation>Lima WG, Brito JCM, da Cruz Nizer WS. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2). Phytother Res. 2021 Feb;35(2):743-750. doi: 10.1002/ptr.6872. Epub 2020 Sep 18. Review.</citation>
    <PMID>32945590</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Trabzon Kanuni Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Betül Değer Kulaksız</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propolis</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

